RESUMO
The acceptance of new and increasingly expensive technologies is a major component of the rising costs of health care. While the practice of anesthesia has been relatively immune from the effects of cost containment, it is inevitable that practitioners will have to justify costly practices. Available pharmacoeconomic methods can be applied to the use of all anesthetic drugs, particularly neuromuscular blocking drugs. Cost-effectiveness analysis allows the practicing anesthesiologist to prioritize the use of neuromuscular blocking drugs to maximize their benefit while reducing unnecessary costs.
Assuntos
Anestesia/economia , Fármacos Neuromusculares não Despolarizantes/economia , Adulto , Controle de Custos , Análise Custo-Benefício , Custos e Análise de Custo , Tomada de Decisões , Custos de Medicamentos , Feminino , Frequência Cardíaca/efeitos dos fármacos , Humanos , Intubação Intratraqueal , Isoquinolinas/administração & dosagem , Isoquinolinas/economia , Masculino , Pessoa de Meia-Idade , Isquemia Miocárdica/fisiopatologia , Isquemia Miocárdica/prevenção & controle , Fármacos Neuromusculares não Despolarizantes/administração & dosagem , Pancurônio/administração & dosagem , Pancurônio/economia , Pipecurônio/administração & dosagem , Pipecurônio/economia , Probabilidade , Fatores de Risco , Brometo de Vecurônio/administração & dosagem , Brometo de Vecurônio/economiaRESUMO
AIM: To study effectiveness of natural combined medicine pumpan in patients with ischemic heart disease (IHD) including cases with concomitant arterial hypertension (AH). MATERIAL AND METHODS: 35 patients with different forms of IHD (myocardial infarction, stable and unstable angina pectoris of functional class III-IV) received conventional treatment combined with pumpan given for 7-11 weeks. Changes in clinical condition, biochemical blood indices, ECG, echo-CG, 24-h arterial pressure monitoring data were investigated. RESULTS: The addition of pumpan to the standard therapy reduced frequency of anginal attacks, improved intracardiac hemodynamics, psychic and adaptive indices. CONCLUSION: Pumpan is a good adjuvant to conventional treatment of various IHD forms including combination of IHD with AH. Pumpan enables reduction in the required doses of beta-blockers, ACE inhibitors, nitrates, sedatives. It also provides hypocoagulatory and hypocholesterolemic effect.
Assuntos
Homeopatia , Hipertensão/complicações , Isquemia Miocárdica/tratamento farmacológico , Adulto , Pressão Sanguínea/efeitos dos fármacos , Colesterol/sangue , Quimioterapia Combinada , Eletrocardiografia , Feminino , Frequência Cardíaca/efeitos dos fármacos , Humanos , Masculino , Pessoa de Meia-Idade , Isquemia Miocárdica/complicações , Isquemia Miocárdica/fisiopatologiaRESUMO
AIM: To study effects of the drug pumpan on exercise tolerance and myocardial ischemia induced by exercise in patients with ischemic heart disease of functional class II-III. MATERIAL AND METHODS: The study included 30 patients with various forms of ischemic heart disease (myocardial infarction, coronary artery bypass grafting) having stable effort angina of functional class II-III. RESULTS: The addition of a compound drug pumpan to a standard antianginal therapy reduced the number of anginal attacks and ST depression at bicycle exercise test. CONCLUSION: Pumpan is an adjuvant medication in conduction of antianginal therapy in ischemic heart disease patients with stable angina of effort of functional class II-III.